CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

Clinical trial NCT05442515 · RECRUITING

Trial details

NCT number: NCT05442515
Sponsor: National Cancer Institute (NCI)
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

B-NHL B-Non Hodgkin Lymphoma Acute Lymphocytic Leukemia Acute Lymphoblastic Leukemia B-precursor ALL B-All Lymphoma, Non-Hodgkin Leukemia, Lymphocytic, B Cell B-Cell Lymphoma B-Cell Leukemia Acute Lymphoid Leukemia

Start date: 2022-12-28
Primary completion: 2027-07-01
Enrollment: 130

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.